The fracture liaison service, a step forward not only in fracture reduction, but also in mortality reduction

W. F. Lems; J. P. van den Bergh; P. P. M. M. Geusens

doi:10.1007/s00198-022-06335-9

The fracture liaison service, a step forward not only in fracture reduction, but also in mortality reduction

W. F. Lems^*
, J. P. van den Bergh
, P. P. M. M. Geusens

^*Corresponding author for this work

Amsterdam UMC - University of Amsterdam
Maastricht UMC+
Hasselt University
University of Amsterdam
Maastricht University
School of Life Sciences

Research output: Contribution to journal › Editorial › Academic › peer-review

17 Downloads (Pure)

Original language	English
Pages (from-to)	1639-1640
Number of pages	2
Journal	Osteoporosis international
Volume	33
Issue number	8
Early online date	2022
DOIs	https://doi.org/10.1007/s00198-022-06335-9
Publication status	Published - 1 Aug 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1007/s00198-022-06335-9

The-fracture-liaison-service-a-step-forward-not-only-in-fracture-reduction-but-also-in-mortality-reduction.pdfFinal published version, 343 KBLicence: CC BY

Cite this

@article{5eb8ac3f59bb408c914cacf15d3f4f49,

title = "The fracture liaison service, a step forward not only in fracture reduction, but also in mortality reduction",

author = "Lems, \{W. F.\} and \{van den Bergh\}, \{J. P.\} and Geusens, \{P. P. M. M.\}",

note = "Funding Information: Prof Lems: speakers{\textquoteright} fee and advisory boards: Amgen, UCB, Eli Lilly, Pfizer, Galapagos. Prof van den Bergh: research funding from UCB and Amgen, consultant for UCB and Amgen. Prof Geusens: lectures and participation in clinical trials: Abbott, Amgen, BMS, Celgene, Janssen, Lilly, MSD, Merck, Novartis, Pfizer, Roche, UCB, Will-Pharma, Fresenius, Viatris, Sandoz, Galapagos.",

year = "2022",

month = aug,

day = "1",

doi = "10.1007/s00198-022-06335-9",

language = "English",

volume = "33",

pages = "1639--1640",

journal = "Osteoporosis international",

issn = "0937-941X",

publisher = "Springer London",

number = "8",

}

TY - JOUR

T1 - The fracture liaison service, a step forward not only in fracture reduction, but also in mortality reduction

AU - Lems, W. F.

AU - van den Bergh, J. P.

AU - Geusens, P. P. M. M.

N1 - Funding Information: Prof Lems: speakers’ fee and advisory boards: Amgen, UCB, Eli Lilly, Pfizer, Galapagos. Prof van den Bergh: research funding from UCB and Amgen, consultant for UCB and Amgen. Prof Geusens: lectures and participation in clinical trials: Abbott, Amgen, BMS, Celgene, Janssen, Lilly, MSD, Merck, Novartis, Pfizer, Roche, UCB, Will-Pharma, Fresenius, Viatris, Sandoz, Galapagos.

PY - 2022/8/1

Y1 - 2022/8/1

UR - https://www.scopus.com/pages/publications/85124749684

UR - https://www.ncbi.nlm.nih.gov/pubmed/35166862

UR - https://www.scopus.com/pages/publications/85124749684

U2 - 10.1007/s00198-022-06335-9

DO - 10.1007/s00198-022-06335-9

M3 - Editorial

C2 - 35166862

SN - 0937-941X

VL - 33

SP - 1639

EP - 1640

JO - Osteoporosis international

JF - Osteoporosis international

IS - 8

ER -

The fracture liaison service, a step forward not only in fracture reduction, but also in mortality reduction

UN SDGs

Access to Document

Other files and links

Cite this